USANA Health Sciences, Inc. (USNA) Earnings Call Transcripts

USANA Health Sciences, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of fiscal year 2026, USANA Health Sciences reported net sales of $204 million, reflecting a 7% sequential growth, driven by active customer growth, particularly in China. The company reaffirmed its full-year guidance for consolidated net sales between $925 million and $1 billion. Earnings per share (EPS) details were not disclosed, but management's confidence in their omnichannel strategy and product launches signals potential for sustained growth, which could positively impact the stock.

Reported metrics

Guidance from management

USANA reaffirmed its full-year 2026 guidance for consolidated net sales between $925 million and $1 billion, indicating confidence in their growth strategy amidst ongoing investments in technology and product development.

What management said

As of this point, we haven't. I'd say the macro environment in China is pretty stable relative to the rest of the globe. They've been somewhat insulated from different inflationary pressures that the rest of the markets have been under. I think it's still a little too early to tell in terms of the Iran conflict and what we might see with fuel prices there. But everything that we've seen and that I'm hearing from our ...

Anthony, this is Kevin. Just to jump in, and I'm going to ask Walter to comment on this as well. To your point and what Kathryn just alluded to, one of the things that I've been very optimistic about is how we're leveraging the expertise and knowledge base from other sales channels into our core business and the learnings that we're gaining from that -- from a direct-to-consumer approach and how that helps lend itsel...

What analysts pressed on

Analysts expressed concerns regarding the elevated customer acquisition costs impacting Hiya's performance and the potential long-term effects of macroeconomic factors on consumer spending. There were inquiries about the pace of new product launches and the effectiveness of marketing strategies in new international markets.

Main topics on the call

• Core Nutritional Business Growth — USANA's core nutritional business saw net sales of $204 million, a 7% sequential increase, attributed to active customer growth in China. Management stated, "the actions we are taking to stabilize the business are beginn...
• Omnichannel Expansion — The company is transitioning to an omnichannel health and wellness platform, with Hiya generating $32 million in Q1 sales and Rise Wellness achieving $14 million, an increase of 143% sequentially. Management noted that "...
• Product Development Pipeline — USANA has over 20 products in development across various segments, focusing on women's and children's health. Management emphasized leveraging insights from different sales channels to enhance product offerings, stating,...
• Technology Modernization Initiatives — The company is investing in technology modernization to improve customer experience and operational efficiency. Management indicated that this would be funded through existing resources, highlighting a commitment to inno...

Read the full USANA Health Sciences, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 31 USANA Health Sciences, Inc. earnings call transcripts on record, spanning February 5, 2020 to August 5, 2026. Based on this history, USANA Health Sciences, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

USNA

Exchange

NYSE

Country

US

Sector

Consumer Staples

Industry

Personal Care Products

Calls on record

31

First call

February 5, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly